Navigation path

Left navigation

Additional tools

Other available languages: FR DE


Brussels, 27th August 2008

Mergers: Commission approves proposed acquisition of certain Schering-Plough animal health products by Pfizer

The European Commission has cleared under the EU Merger Regulation the proposed acquisition of certain animal health assets of Schering-Plough (SP Assets) by Pfizer, both U.S. pharmaceutical companies. After examining the operation, the Commission concluded that the proposed transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.

Pfizer is a global healthcare company, active in human and animal health products. The SP Assets comprise a broad range of products for both companion and farm animals including various vaccines, specialty pharmaceuticals and parasiticides. Schering-Plough is pursuing the sale of these assets following commitments it made in the context of the European Commission's investigation of its acquisition of Organon BS (see IP/07/1489).

The overlaps between the activities of Pfizer and the SP Assets are limited in most markets. The Commission’s examination of the proposed transaction showed that the new entity would continue to face several significant competitors in all the relevant markets for animal vaccines and pharmaceuticals and that farmers and veterinarians across the EEA would continue to have access to alternative suppliers post-merger.

The Commission therefore concluded that the creation of the new entity would not give rise to any competition concerns in the markets concerned.

More information on the case will be available at:

Side Bar